Drugs & Targets FDA approves Keytruda + pemetrexed + chemo in first-line mesothelioma indication September 20, 2024Vol.50 No.35
Drugs & Targets Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager August 09, 2024Vol.50 No.32
Drugs & Targets CHMP adopts positive opinion of Keytruda + Padcev for unresectable or metastatic urothelial carcinoma August 02, 2024Vol.50 No.31
Drugs & Targets Merck, Qure.ai collaborate to expand lung cancer detection via AI June 28, 2024Vol.50 No.26
Clinical Roundup Keytruda improves OS for high-risk early-stage TNBC in phase III trial May 31, 2024Vol.50 No.22
Clinical Roundup Lifileucel + pembrolizumab show promise for advanced melanoma in data from phase II study May 31, 2024Vol.50 No.22
Clinical Roundup Merck discontinues arm of phase III trial evaluating vibostolimab + pembrolizumab in adjuvant high-risk melanoma May 17, 2024Vol.50 No.20
Clinical Roundup Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication January 05, 2024Vol.50 No.01
Clinical Roundup Merck’s Welireg reached primary endpoint of PFS in phase III trial for RCC September 08, 2023Vol.49 No.33
